The global market is expected to enjoy a valuation of USD 153.6 Million by the end of the year 2023, and further expand at a CAGR of 10.3% to reach a valuation of USD 408.3 Million by the year 2033. According to the recent study by Future Market Insights, pure gold markers are leading the market with an expected share of about 62.50% in the year 2023, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 139.24 Million |
| Market Value 2023 | USD 153.6 Million |
| Market Value 2033 | USD 408.3 Million |
| CAGR 2023 to 2033 | 10.3% |
| Market Share of Top 5 Countries | 57.8% |
| Key Market Players | Eckert & Ziegler BEBIG; Innovative Oncology Solutions; Boston Scientific; IBA Dosimetry; Best Medical International, Inc.; IZI Medical Products; Carbon Medical Technologies; CIVCO; alphaXRT; Nanovi A/S; Stellar Medical |
Radiation oncologists can benefit significantly from fiducial markers in two ways. They start by pinpointing the tumour’s precise location at each stage of the patient's breathing cycle. Second, they enable the radiation oncologist to guarantee that the delivery is precisely in the proper area every day because imaging is provided on the radiation treatment equipment itself. Smaller margins of healthy tissues within the treated areas are made possible by these two benefits, which reduces side effects.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for fiducial markers was approximately 1.5% of the overall ~USD 6.5 Billion of the global radiotherapy market in 2022.
Fiducial markers, which are incredibly tiny objects approximately the size of rice grains, can target tumours or other cancerous tissues while excluding healthy ones. A fiducial marker is a device used in radiotherapy to locate the surgical site and administer precise radiation doses. Percutaneous implantation of fiducial markers has been attempted, but these operations have been linked to a high rate of pneumothorax and chest drain placement.
Fiducial markers can be placed easily and safely during bronchoscopy. The fiducial marker can help the doctor locate the tumour accurately so that the patient will receive the right amount of radiation without injuring nearby tissue.
There are numerous different types of fiducial markers, including markers made of metal or polymers, among others. The fiducial marker technology may also offer a 3D image of the fiducials together with a report outlining the precise diagnosis and course of therapy.
The main use of fiducial markers in radiotherapy is to identify lung tumours, also known as lung fiducial markers. When air is wedged between the lung and the chest wall after lung fiducial markers are implanted, the result is a pneumothorax, or collapsed lung. A chest tube may need to be inserted in order to remove the air pocket and re-expand the lung.
Patients with prostate cancer receive treatment using prostate fiducial markers. Rectal bleeding, blood in the urine, and discomfort or stinging when peeing can all result from the improper implementation of prostate fiducial markers in the prostate. The second most common malignancy in men worldwide is prostate cancer. As a result, there is a growing demand for prostate fiducial markers.
The use of cutting-edge technology in hospitals, hospital outpatient facilities, and the medical industry has fuelled the rise of fiducial marker producers over the past ten years, despite the fact that modern lifestyles, a lack of healthy behaviour, and other factors have increased cancer risks. Fiducial markers in radiotherapy are likely to become more popular over the next few years, which will raise demand for manufacturers and suppliers.
Increased awareness of early detection and effective treatment for cancer, as well as rising cancer incidence rates, are driving up demand for fiducial markers. As manufacturers work to offer a wider selection of products, demand for fiducial markers for various disease indication is quickly rising. Thus, owing to the aforementioned factors, the global fiducial markers market is expected to grow at a CAGR of 10.27% during the forecast period from 2023 to 2033.
H1-H2 Update
| Market Statistics | Details |
|---|---|
| Jan - Jun (H1), 2021 (A) | 9.23% |
| Jul - Dec (H2), 2021 (A) | 11.35% |
| Jan - Jun (H1),2022 Projected (P) | 7.40% |
| Jan - Jun (H1),2022 Outlook (O) | 8.15% |
| Jul - Dec (H2), 2022 Outlook (O) | 12.12% |
| Jul - Dec (H2), 2022 Projected (P) | 11.59% |
| Jan - Jun (H1), 2023 Projected (P) | 8.53% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 75↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | (-) 108↓ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 53↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 77↑ |
Fiducial markers are used in image-based radiotherapy to target malignant areas while sparing healthy tissues. Due to an increase in cancer diagnoses, there is a rising demand for fiducial markers on a global scale.
With over 4 million occurrences annually, lung and breast cancers are the most prevalent cancers in adults globally. As a result, governments and healthcare organisations are working harder to develop extremely complicated procedures to ease the pressure.
Evidence suggests that patients with Stage IV non-small cell lung cancer who have only a few extrapulmonary metastases live longer while receiving extensive radiation therapy. On the other hand, open surgery has proven to be effective for treating cervical malignancies in their early stages. As a result, fiducial markers are in high demand.
Rising demand from hospitals for highly advanced fiducial markers, increasing investments from governments and non-profit organisations on research and development, advanced medical equipment, and other products for hospitals, are fuelling the need for fiducial markers.
Principal Consultant
The cost of fiducial markers is typically prohibitive for most people. Commoners might not be able to afford the high operating costs as a result, which would restrict the market growth for fiducial markers.
The use of fiducial markers has a number of drawbacks. These procedures are not suitable for everyone due to their invasiveness. Fiducial markers also degrade image quality during scanning, making tumour identification challenging. The market's expansion is also constrained by a lack of expertise.
| Country | The USA |
|---|---|
| Market Share (2023) | 22.8% |
| Market Share (2033) | 20.7% |
| BPS Analysis | -201 |
| Country | China |
|---|---|
| Market Share (2023) | 12.7% |
| Market Share (2033) | 14.4% |
| BPS Analysis | 172 |
| Country | Japan |
|---|---|
| Market Share (2023) | 8.8% |
| Market Share (2033) | 9.8% |
| BPS Analysis | 93 |
| Country | Germany |
|---|---|
| Market Share (2023) | 6.6% |
| Market Share (2033) | 6.1% |
| BPS Analysis | -55 |
| Country | UK |
|---|---|
| Market Share (2023) | 6.5% |
| Market Share (2033) | 6.1% |
| BPS Analysis | -42 |
The USA is set to obtain a share of around 22.8% in the global market, in 2023.
This is brought on by an increase in cancer treatment facilities, radiation treatment facilities, and advanced manufacturing facilities. The United States will have 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in 2022, according to Cancer Facts & Figures (2022), an educational companion to Cancer Statistics (2022), a scientific article published in the journal of the American Cancer Society.
These developments will probably accelerate the growth of the fiducial marker market in the United States of America over the next ten years. Likewise, growing market growth is being fuelled by significant manufacturers' presence and expanding fiducial marker sales in the USA
Germany is set to hold a market share of nearly 6.6% in the global fiducial markers market in 2023.
In Europe, more than 3.2 million people are given a cancer diagnosis each year. Breast and colorectal cancer are the most prevalent types of the disease because of population ageing and a rise in obesity prevalence. Additionally, it is projected that extending CE approval of different fiducial markers will help regional market expansion. For instance, in March 2020, Nanovi A/BioXmark S's liquid fiducial marker received CE approval. These developments are set to expand the market in Germany over the projected period.
China will hold a share of around 12.7% in the global market, in 2023.
In China, lung cancer is the most common type of cancer. The incidences of stomach, liver, and esophageal cancer have slowly decreased in China, whereas colorectal cancer, prostate cancer in men, and other seven cancer types in women have increased.
Cut case-fatality rates helped to lower cancer mortality in the nation, while increases in the adult population and population ageing were significant predictors of incremental cancer fatalities in various cancer types. Thus, during the anticipated time, these variables cause the fiducial markers market to rise quickly.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The pure gold markers segment leads the market and is expected to hold a share of around 62.5% globally, in 2023.
Fiducial markers made of pure gold are most frequently employed in various cancer treatment procedures. Gold fiducial markers dramatically enhance target visibility during brachytherapy and external beam radiation treatments. It also improved patients' feelings.
The manufacturer of distinctive fiducial markers, InnoMedicus, is the source of the Gold Anchor Marker. It is frequently used for Cyberknife procedures on the liver, pancreas, lungs, adrenal gland, and prostate gland, to name a few. More than six out of ten cancer procedures are likely to utilise gold markers.
Photon therapy segment is set to hold a global market share of around 51.9% in 2023. In order to prepare for radiation therapy, small metal items called fiducial markers are placed in or close to a tumour using imaging guidance. The markers enable the treatment team to give the highest radiation dose to the tumour while sparing healthy tissue and aid in more precise tumour localization. This factor is set to propel the segment growth over the forecast period.
Prostrate site is projected to hold a market share of around 72.2% in the global market in 2023.
To increase contrast and subsequently treatment setup and prostate targeting, fiducial markers (FMs) have been designed and surgically inserted within the prostate gland before radiotherapy planning. There are several different strategies for using prostate FMs when they are used in clinical practise.
The surgical process required to implant FMs into the prostate contains risks such as discomfort, haemorrhage, inflammation, and infection, but overall the operation is safe and well tolerated.
Radiotherapy centers is set to hold a market share of around 39.1% in the global market in 2023.
Fiducial markers provide more precise radiation therapy, increasing the likelihood that the radiation will successfully kill cancer cells and decreasing the likelihood that it would harm healthy cells, minimising the procedure's negative effects.
The use of fiducial markers enables more precise and concentrated radiation therapy for the tumour. It can also significantly shorten the time a patient needs endure radiation therapy. Sometimes a radiation treatment that would normally take five weeks can be completed in just five days, thus propelling the segment share within the global market.
Major firms like CIVCO are releasing implantable fiducial marker solutions with a range of features and settings that prevent the markers' post-placement movement.
Instances of key developmental strategies by the industry players in the fiducial markers market are given below:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the fiducial markers space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Modality, Disease Site, End User, and Region |
| Key Companies Profiled | Eckert & Ziegler BEBIG; Innovative Oncology Solutions; Boston Scientific; IBA Dosimetry; Best Medical International, Inc.; IZI Medical Products; Carbon Medical Technologies; CIVCO; alphaXRT; Nanovi A/S; Stellar Medical |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The projected revenue of the market by 2033 is USD 408.3 million.
The market CAGR for 2033 is projected to be 10.3%.
The market is valued at USD 153.6 million in 2023.
North America holds a significant market share.
The challenge for the fiducial markers market is the high cost of fiducial markers.
1. Executive Summary | Fiducial Markers Market 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product 7.1. Polymer Based Markers 7.2. Metal Based Markers 7.3. Pure Gold Markers 7.4. Liquid Based Markers 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality 8.1. Photon Therapy 8.2. Proton Therapy 8.3. Tomotherapy 8.4. Cyberknife 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease Site 9.1. Head & Neck 9.2. Breast 9.3. Lung 9.4. Abdomen 9.5. Prostate 9.6. Kidney 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 10.1. Hospitals 10.2. Cancer Research Institutes 10.3. Radiotherapy Centers 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. East Asia 11.5. South Asia 11.6. Oceania 11.7. Middle East and Africa (MEA) 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. Oceania Market 2017 to 2022 and Forecast 2023 to 2033 18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Market Structure Analysis 20. Competition Analysis 20.1. Eckert & Ziegler BEBIG 20.2. Innovative Oncology Solutions 20.3. Boston Scientific 20.4. IBA Dosimetry 20.5. Best Medical International, Inc. 20.6. IZI Medical Products 20.7. Carbon Medical Technologies 20.8. CIVCO 20.9. alphaXRT 20.10. Nanovi A/S 20.11. Stellar Medical 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Fiducial Markers Market
